PHAS - PhaseBio Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

PhaseBio Pharmaceuticals, Inc.

1 Great Valley Parkway
Suite 30
Malvern, PA 19355
United States
610 981 6500
http://phasebio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Mr. Jonathan P. MowPres, CEO & Director678.78kN/A1965
Mr. John P. SharpChief Financial Officer548.51kN/A1965
Dr. John S. LeeChief Medical Officer581.5kN/A1968
Mr. Kristopher L. HansonVP, Head of Legal & Corp. Sec.N/AN/A1972
Mr. Michael B. YorkVP of Corp. Devel. & Commercial StrategyN/AN/A1965
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Corporate Governance

PhaseBio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.